227 related articles for article (PubMed ID: 32234489)
1. Defining and Targeting Adaptations to Oncogenic KRAS
Santana-Codina N; Chandhoke AS; Yu Q; Małachowska B; Kuljanin M; Gikandi A; Stańczak M; Gableske S; Jedrychowski MP; Scott DA; Aguirre AJ; Fendler W; Gray NS; Mancias JD
Cell Rep; 2020 Mar; 30(13):4584-4599.e4. PubMed ID: 32234489
[TBL] [Abstract][Full Text] [Related]
2. Cell Type-specific Adaptive Signaling Responses to KRAS
Solanki HS; Welsh EA; Fang B; Izumi V; Darville L; Stone B; Franzese R; Chavan S; Kinose F; Imbody D; Koomen JM; Rix U; Haura EB
Clin Cancer Res; 2021 May; 27(9):2533-2548. PubMed ID: 33619172
[TBL] [Abstract][Full Text] [Related]
3. KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition.
Misale S; Fatherree JP; Cortez E; Li C; Bilton S; Timonina D; Myers DT; Lee D; Gomez-Caraballo M; Greenberg M; Nangia V; Greninger P; Egan RK; McClanaghan J; Stein GT; Murchie E; Zarrinkar PP; Janes MR; Li LS; Liu Y; Hata AN; Benes CH
Clin Cancer Res; 2019 Jan; 25(2):796-807. PubMed ID: 30327306
[TBL] [Abstract][Full Text] [Related]
4. KRAS
Lou K; Steri V; Ge AY; Hwang YC; Yogodzinski CH; Shkedi AR; Choi ALM; Mitchell DC; Swaney DL; Hann B; Gordan JD; Shokat KM; Gilbert LA
Sci Signal; 2019 May; 12(583):. PubMed ID: 31138768
[TBL] [Abstract][Full Text] [Related]
5. More to the RAS Story: KRAS
Lietman CD; Johnson ML; McCormick F; Lindsay CR
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-13. PubMed ID: 35561303
[TBL] [Abstract][Full Text] [Related]
6. Modulation of the proteostasis network promotes tumor resistance to oncogenic KRAS inhibitors.
Lv X; Lu X; Cao J; Luo Q; Ding Y; Peng F; Pataer A; Lu D; Han D; Malmberg E; Chan DW; Wang X; Savage SR; Mao S; Yu J; Peng F; Yan L; Meng H; Maneix L; Han Y; Chen Y; Yao W; Chang EC; Catic A; Lin X; Miles G; Huang P; Sun Z; Burt B; Wang H; Wang J; Yao QC; Zhang B; Roth JA; O'Malley BW; Ellis MJ; Rimawi MF; Ying H; Chen X
Science; 2023 Sep; 381(6662):eabn4180. PubMed ID: 37676964
[TBL] [Abstract][Full Text] [Related]
7. Targeting Kras
Christensen JG; Olson P; Briere T; Wiel C; Bergo MO
J Intern Med; 2020 Aug; 288(2):183-191. PubMed ID: 32176377
[TBL] [Abstract][Full Text] [Related]
8. An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer.
Wang H; Lv Q; Xu Y; Cai Z; Zheng J; Cheng X; Dai Y; Jänne PA; Ambrogio C; Köhler J
EBioMedicine; 2019 Nov; 49():106-117. PubMed ID: 31668570
[TBL] [Abstract][Full Text] [Related]
9. Heterogeneity and mutation in KRAS and associated oncogenes: evaluating the potential for the evolution of resistance to targeting of KRAS G12C.
Cannataro VL; Gaffney SG; Stender C; Zhao ZM; Philips M; Greenstein AE; Townsend JP
Oncogene; 2018 May; 37(18):2444-2455. PubMed ID: 29453361
[TBL] [Abstract][Full Text] [Related]
10. A proteomic and phosphoproteomic landscape of KRAS mutant cancers identifies combination therapies.
Liu Z; Liu Y; Qian L; Jiang S; Gai X; Ye S; Chen Y; Wang X; Zhai L; Xu J; Pu C; Li J; He F; Huang M; Tan M
Mol Cell; 2021 Oct; 81(19):4076-4090.e8. PubMed ID: 34375582
[TBL] [Abstract][Full Text] [Related]
11. Quantitative Systems Pharmacology Analysis of KRAS G12C Covalent Inhibitors.
Stites EC; Shaw AS
CPT Pharmacometrics Syst Pharmacol; 2018 May; 7(5):342-351. PubMed ID: 29484842
[TBL] [Abstract][Full Text] [Related]
12. Resistance looms for KRAS G12C inhibitors and rational tackling strategies.
Zhang J; Zhang J; Liu Q; Fan XX; Leung EL; Yao XJ; Liu L
Pharmacol Ther; 2022 Jan; 229():108050. PubMed ID: 34864132
[TBL] [Abstract][Full Text] [Related]
13. KRAS mutation in pancreatic cancer.
Luo J
Semin Oncol; 2021 Feb; 48(1):10-18. PubMed ID: 33676749
[TBL] [Abstract][Full Text] [Related]
14. KRAS-G12C covalent inhibitors: A game changer in the scene of cancer therapies.
Naim N; Moukheiber S; Daou S; Kourie HR
Crit Rev Oncol Hematol; 2021 Dec; 168():103524. PubMed ID: 34800654
[TBL] [Abstract][Full Text] [Related]
15. Wild-type KRAS is a novel therapeutic target for melanoma contributing to primary and acquired resistance to BRAF inhibition.
Dietrich P; Kuphal S; Spruss T; Hellerbrand C; Bosserhoff AK
Oncogene; 2018 Feb; 37(7):897-911. PubMed ID: 29059159
[TBL] [Abstract][Full Text] [Related]
16. Exploring Targeted Degradation Strategy for Oncogenic KRAS
Zeng M; Xiong Y; Safaee N; Nowak RP; Donovan KA; Yuan CJ; Nabet B; Gero TW; Feru F; Li L; Gondi S; Ombelets LJ; Quan C; Jänne PA; Kostic M; Scott DA; Westover KD; Fischer ES; Gray NS
Cell Chem Biol; 2020 Jan; 27(1):19-31.e6. PubMed ID: 31883964
[TBL] [Abstract][Full Text] [Related]
17. Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers.
Hao HX; Wang H; Liu C; Kovats S; Velazquez R; Lu H; Pant B; Shirley M; Meyer MJ; Pu M; Lim J; Fleming M; Alexander L; Farsidjani A; LaMarche MJ; Moody S; Silver SJ; Caponigro G; Stuart DD; Abrams TJ; Hammerman PS; Williams J; Engelman JA; Goldoni S; Mohseni M
Mol Cancer Ther; 2019 Dec; 18(12):2368-2380. PubMed ID: 31439712
[No Abstract] [Full Text] [Related]
18. Cytotoxic activity of KRAS inhibitors in combination with chemotherapeutics.
Hamilton G; Plangger A
Expert Opin Drug Metab Toxicol; 2021 Sep; 17(9):1065-1074. PubMed ID: 34347509
[TBL] [Abstract][Full Text] [Related]
19. KRAS G12C inhibition and innate immune targeting.
Tani T; Kitajima S; Conway EB; Knelson EH; Barbie DA
Expert Opin Ther Targets; 2021 Mar; 25(3):167-174. PubMed ID: 33703985
[TBL] [Abstract][Full Text] [Related]
20. Efficient targeted oncogenic KRAS
Yang F; Wen Y; Wang C; Zhou Y; Zhou Y; Zhang ZM; Liu T; Lu X
Eur J Med Chem; 2022 Feb; 230():114088. PubMed ID: 35007863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]